XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Sales:        
Total sales, net $ 3,265 $ 3,826 $ 10,999 $ 10,761
Product cost of goods sold 1,427 1,451 4,919 4,735
Gross profit 1,838 2,375 6,080 6,026
Operating expenses:        
Research and development 11 41 64 108
Sales and marketing 1,715 1,835 5,086 5,860
General and administrative 1,228 956 5,135 5,049
Total operating expenses 2,954 2,832 10,285 11,017
Operating loss (1,116) (457) (4,205) (4,991)
Non-cash gain on changes in fair value of warrant liability 0 2,414 216 4,470
Non-cash gain on changes in fair value of combined derivative liability 0 0 40 0
Non-cash gain on changes in fair value of contingent liability 0 0 0 219
Non-cash loss on modification of common stock warrants 0 (1,922) (285) (1,922)
Other expense, net (641) (171) (1,298) (178)
Net loss (1,757) (136) (5,532) (2,402)
Less: Increase to accumulated deficit due to adjustment to Series B Preferred Stock conversion price 0 (5,657) (1,802) (5,657)
Less: Increase to accumulated deficit due to adjustment to Series C Preferred Stock conversion price 0 0 (194) 0
Net loss attributable to common stockholders $ (1,757) $ (5,793) $ (7,528) $ (8,059)
Net loss per share attributable to common stockholders (basic and diluted)* (in dollars per share) $ (0.37) $ (3.61) [1] $ (2.27) $ (5.32) [1]
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock (basic and diluted)* (in shares) 4,692 1,604 [1] 3,311 1,514 [1]
Product [Member]        
Sales:        
Total sales, net $ 3,255 $ 3,816 $ 10,971 $ 10,743
Product and Service, Other [Member]        
Sales:        
Total sales, net $ 10 $ 10 $ 28 $ 18
[1] After giving retroactive effect to a 1-for-35 reverse stock split that became effective November 15, 2022.